pleased with these
first results from the liraglutide phase 3 programme, showing that
liraglutide provides improved glucose control compared to insulin
glargine while, at the same time, leading to significant weight
loss."
Novo Nordisk expects to announce headline results from the
remaining four LEAD(TM) studies during the second half of 2007 and
the first quarter of 2008. Detailed results from the full LEAD(TM)
programme are expected to be published in peer reviewed journals
and communicated at future scientific meetings.
The results of the phase 3 trial do not change Novo Nordisk's
expectations for the company's financial results for 2007, which
were provided on 2 May in connection with the release of the
financial results for the first three months of 2007.
Conference call
At 12.30 pm CET today, corresponding to 6.30 am EDT, a conference
call for investors will be held. Investors will be able to listen
in via a link on novonordisk.com, which can be found under
'Investors - Download centre'.
About liraglutide, LEAD(TM) and HbA1c
Liraglutide is a once-daily human analogue of the naturally
occurring hormone Glucagon-Like Peptide-1 (GLP-1). The compound is
being developed by Novo Nordisk for the treatment of type 2
diabetes, and is currently in phase 3 development. Liraglutide
works by stimulating the release of insulin only when glucose
levels become too high. In contrast to most other antidiabetic
treatments liraglutide also leads to weight loss instead of weight
increase.
The LEAD(TM) programme (Liraglutide Effect and Action in Diabetes)
is comprised of five randomised, controlled, double-blind studies
conducted in more than 40 countries. The programme includes around
3,800 patients with type 2 diabetes whose blood glucose is
inadequately controlled.
HbA1c is an abbreviation for glycated haemoglobin HbA1c. The level
of HbA1c reflects the average blood glucose level ov
'"/>Page: 1 2 3 4 Related medicine technology :1.
Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog
Liraglutide, Brings Patients to A1c Target2.
Positive results from placebo-controlled phase IIa study in
patients suffering from house dust mite allergy3.
Placebo-controlled Phase IIa Study with the Immunotherapeutic
CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in
Hay Fever Patients4.
Independent publication supports the profile of CeNeS phase II
compound, CNS 51615.
Isotechnikas independent data monitoring committee conducts review
of phase 2b kidney transplant trial6.
First single breast cancer study to show significant survival
benefit for women switching from tamoxifen to Arimidex7.
Cipralex demonstrates superiority to duloxetine for acute treatment
of depression in new study8.
2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with
AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion